PhD Scientific Days 2024
Budapest, 9-10 July 2024
Pathological and Oncological Sciences III.
Inter-tumoral Comparative Expression Analysis of Subtype-defining Proteins and Therapeutic Targets in Small Cell Lung Cancer
Előadó neve
Dr. Pozonec, Maria Dorothea
Neptun code
WMNSLK
Előadó munkahelye
Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary ; National Koranyi Institute of Pulmonology, Budapest, Hungary
Előadó telefonszáma
06203199835
Előadó e-mail címe
p.m.d.555@hotmail.com
Az előadás címe
Inter-tumoral Comparative Expression Analysis of Subtype-defining Proteins and Therapeutic Targets in Small Cell Lung Cancer
Szerző(k) neve és munkahelye
Pozonec Mária Dorothea1,5, Téglás Vivien1,5, Csende Kristóf1, Ferencz Bence1,5, Ferenczy Anita1, Megyesfalvi Evelyn2, Pozonec Veronika1,2, Kristiina Boettiger3, Pipek Orsolya4, Fillinger János5, Rényi-Vámos Ferenc1,5,6, Megyesfalvi Zsolt1,3,5, Balázs Döme1,3,5,7
1: Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary
2: Department of Clinical Pharmacology, National Institute of Oncology, Chest and Abdominal Tumors Chemotherapy "B", Budapest, Hungary
3: Department of Thoracic Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria
4: Department of Physics of Complex Systems, Eotvos Lorand University, Budapest, Hungary
5: National Koranyi Institute of Pulmonology, Budapest, Hungary
6: National Institute of Oncology and National Tumor Biology Laboratory, Budapest, Hungary
7: Department of Translational Medicine, Lund University, Lund, Sweden
Bemutatás módja
Szóbeli
Szekció
Pathological and Oncological Sciences III.
Language of the presentation
English
Preferred session
Pathological and Oncological Sciences
Összefoglaló szövege
Introduction: Small cell lung cancer (SCLC) represents one of the most aggressive cancers. It is characterized by its tendency for early metastatic spread, particularly to regional lymph nodes. However, the molecular landscape of the primary tumor does not necessarily align with the expression of subtype- and therapy-related markers of corresponding lymph node metastases.
Aims: This study aimed to investigate the differences in molecular expression patterns between primary SCLC tumors and their lymph node metastases.
Methods: 32 metastatic SCLC patients who underwent surgical resections between 1978 and 2013 at the National Korányi Institute of Pulmonology with available tissue specimens were included in our study. The samples from both the primary tumor and the lymph node metastasis were evaluated by RNA expression analysis and IHC.
Result: When comparing the expression levels between primary tumors and their lymph node metastases, we found a significant difference in the expression of DLL3 (p=0.008) and NeuroD1 (p<0.001) in lymph node metastases compared to primary tumors based on the IHC staining. However, neither of these tendencies could be verified with RNAseq. When observing the molecular subtype of samples, we found a tendency for change between the primary tumor and its lymph node metastasis. The most common changes were from SCLC-A to either SCLC-AN or SCLC-QN and from SCLC-QN to SCLC-AN and SCLC-N due to tumoral evolution or intratumoral heterogeneity, respectively.
Conclusion: This study highlights the discordance in protein expression between primary tumors and corresponding lymph node metastases in SCLC. It also sheds light on the phenotype switching between various SCLC subtypes during the disease progression. The knowledge is beneficial for uncovering molecular mechanisms driving metastatic spread in SCLC and could influence the development of targeted therapies and prognostic markers.
Funding:
BD and ZM: Hungarian National Research, Development, and Innovation Office (2020‐1.1.6‐JÖVŐ, TKP2021‐EGA‐33, FK‐143751, FK-147045)
ZM: New National Excellence Program of the Ministry for Innovation and Technology of Hungary (UNKP‐20‐3, UNKP‐21‐3, UNKP-23-5); Bolyai Research Scholarship of the Hungarian Academy of Sciences, International Association for the Study of Lung Cancer/International Lung Cancer Foundation Young Investigator Grant (2022)
University
Semmelweis University
Supervisor
Dr. Döme Balázs Ph.D.
Publication of my abstract
I do not give consent to the publication of my abstract on the website of the congress.
Kind
Szabad
Status
elfogadva
Accepted presentation method
szóbeli
Előadás fájl jóváhagyás
nem rendelkezett róla
Előadó
8059
Start
10:15
End
10:25